BC Week In Review | Apr 12, 2019
Clinical News

Merrimack discontinues last clinical candidate

Merrimack discontinued development of MM-310 -- the company's last remaining product in clinical testing -- after a safety update showed that a Phase I trial in solid tumor patients "would not be able to reach...
BC Week In Review | Jun 29, 2018
Clinical News

Merrimack discontinues pancreatic cancer candidate after Phase II miss

Merrimack Pharmaceuticals Inc. (NASDAQ:MACK) reported that first-line treatment with istiratumab (MM-141) missed the primary and secondary endpoints in the Phase II CARRIE trial to treat metastatic pancreatic cancer. The company said it will discontinue the...
BC Extra | Jun 25, 2018
Clinical News

Merrimack falls on Phase II pancreatic cancer failure

Merrimack Pharmaceuticals Inc. (NASDAQ:MACK) lost $4.01 (44%) to $5.14 on Monday after reporting that first-line treatment with istiratumab (MM-141) missed the primary and secondary endpoints in the Phase II CARRIE trial to treat metastatic pancreatic...
BC Innovations | Mar 13, 2018
Distillery Therapeutics


INDICATION: Breast cancer Studies in mice suggest a peptide-based EPHA2 agonist conjugated to paclitaxel could help treat triple-negative breast cancer (TNBC). Conjugation of an EPHA2 agonist peptide to the generic chemotherapy paclitaxel and in vitro...
BC Week In Review | Dec 22, 2017
Clinical News

Stemline reports additional Phase II data for SL-701 in GBM

In November, Stemline Therapeutics Inc. (NASDAQ:STML) reported additional data from the two-stage Phase II STML-701-0114 trial of SL-701 as a second-line treatment of glioblastoma multiforme (GBM). Data were presented at the Society of Neuro-Oncology meeting...
BioCentury | Jun 9, 2017

Pedaling to the clinic

With lead candidate BT-1718 expected to enter the clinic this year, Bicycle Therapeutics Ltd. has padded its coffers with a £40 million ($51.3 million) series B to expand its pipeline of bicyclic peptides for cancer....
BC Week In Review | Mar 30, 2017
Clinical News

MM-310: Ph I started

Merrimack began an open-label, U.S. Phase I trial to evaluate IV MM-310 on day 1 of each 21-day cycle. A dose-escalation part will determine the MTD of MM-310 alone in up to 34 patients. The...
BC Extra | Jan 20, 2017
Financial News

Stemline raises $45M in follow-on

Stemline Therapeutics Inc. (NASDAQ:STML) raised $45 million through the sale of 4.5 million shares at $10 in a follow-on underwritten by Jefferies, Cowen, Ladenburg Thalmann, H.C. Wainwright, Roth Capital Partners, Joseph Gunnar and Aegis Capital....
BC Week In Review | Jan 12, 2017
Company News

Merrimack, Ipsen deal

Ipsen will acquire the commercial business of Merrimack, including U.S. rights to Onivyde irinotecan and Merrimack’s generic doxorubicin product. The companies expect the deal to close this quarter. Merrimack markets Onivyde to treat metastatic pancreatic...
BC Extra | Jan 10, 2017
Company News

Ipsen acquiring Merrimack's marketed products

Ipsen Group (Euronext:IPN; Pink:IPSE) is acquiring the commercial business of Merrimack Pharmaceuticals Inc. (NASDAQ:MACK) for $575 million up front and up to $450 million in milestones. The deal includes U.S. rights to Onivyde irinotecan, as...
Items per page:
1 - 10 of 36